TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02607384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eyeglass wearing
Description: Children found to require eyeglasses will be given two pairs free of charge
Study: NCT04955041

Intervention type: OTHER
Intervention: MRI
Description: T2\* MRI

Intervention type: OTHER
Intervention: MRI
Description: T2\* MRI
Study: NCT04425239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Continuous administation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Intermittent administation
Study: NCT02607384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orthoptic exercises
Description: Children found to have convergence insufficiency will be prescribed orthoptic exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialist referral
Description: Children found to any other eye condition will be referred to a pediatric eye care specialist
Study: NCT04147702

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance analysis
Description: Balance analysis is assessment method to estimate deterioration of postural control.
Study: NCT01846312

Intervention type: OTHER
Intervention: No treatment given
Description: The participants will not receive any treatment.
Study: NCT01833507

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Exercise
Description: Behavioral Goal Setting

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics. Participants will subsequently be given entry into the active intervention at the 2-month check.
Study: NCT01262105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Barrier System Device
Description: Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the site.
Study: NCT02740985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: AZD4635 will be administered orally as a nanosuspension or capsule on a continuous schedule in Arms A, B, C, D, E, F, G, H, I, J, K, KD, L, AA, and EA. The AZD4635 nanoparticle drug product will be constituted extemporaneously as an oral suspension by the patient immediately prior to dosing. In Arms CA, CB, and CC AZD4635 will be administered as 75 mg or 50 mg capsules. Additionally, in Arm CA, AZD4635 will also be administered at 150 mg and 200 mg, or a lower dose of 125 mg or 100 mg may be given.
Study: NCT04147702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance analysis
Description: Balance analysis is assessment method to estimate deterioration of postural control.
Study: NCT00392860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natural-Fit
Description: Ergonomic handrim for wheelchairs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PalmRim
Description: Ergonomic handrim for wheelchair
Study: NCT02740985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: AZD4635 will be administered orally as a nanosuspension or capsule on a continuous schedule in Arms A, B, C, D, E, F, G, H, I, J, K, KD, L, AA, and EA. The AZD4635 nanoparticle drug product will be constituted extemporaneously as an oral suspension by the patient immediately prior to dosing. In Arms CA, CB, and CC AZD4635 will be administered as 75 mg or 50 mg capsules. Additionally, in Arm CA, AZD4635 will also be administered at 150 mg and 200 mg, or a lower dose of 125 mg or 100 mg may be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: AZD4635 will be administered orally as a nanosuspension or capsule on a continuous schedule in Arms A, B, C, D, E, F, G, H, I, J, K, KD, L, AA, and EA. The AZD4635 nanoparticle drug product will be constituted extemporaneously as an oral suspension by the patient immediately prior to dosing. In Arms CA, CB, and CC AZD4635 will be administered as 75 mg or 50 mg capsules. Additionally, in Arm CA, AZD4635 will also be administered at 150 mg and 200 mg, or a lower dose of 125 mg or 100 mg may be given.
Study: NCT00392860

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Handrim Control Group
Description: Participants were given a new standard handrim to test. This intervention group is the control group.
Study: NCT04383483

Intervention type: OTHER
Intervention: COVICU
Description: COVICU
Study: NCT03879278

Intervention type: DRUG
Group type: OTHER
Intervention: NPT189
Description: NPT189 is a recombinant immunoglobulin Fc fusion of GAIM (GAIM-IgG1Fc) as a potential treatment for peripheral amyloidosis.

Intervention type: DRUG
Group type: OTHER
Intervention: NPT189
Description: NPT189 is a recombinant immunoglobulin Fc fusion of GAIM (GAIM-IgG1Fc) as a potential treatment for peripheral amyloidosis.
Study: NCT03879278

Intervention type: DRUG
Group type: OTHER
Intervention: NPT189
Description: NPT189 is a recombinant immunoglobulin Fc fusion of GAIM (GAIM-IgG1Fc) as a potential treatment for peripheral amyloidosis.
Study: NCT03415568

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LCT oil
Description: LCT muffin was provided to the study participants. The LCT muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was LCT.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCDG oil
Description: MCDG muffin was provided to the study participants. The MCDG muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was MCDG.
Study: NCT02940912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apomorphine
Description: cross-over with start with Apokinon in the 1st phase- in the 2nd phase of continuous treatment with Physiologic Serum.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cross-over with start with.Physiologic Serum in the 1st phase- in the 2nd phase of continuous treatment with Apokinon.
Study: NCT02740985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: AZD4635 will be administered orally as a nanosuspension or capsule on a continuous schedule in Arms A, B, C, D, E, F, G, H, I, J, K, KD, L, AA, and EA. The AZD4635 nanoparticle drug product will be constituted extemporaneously as an oral suspension by the patient immediately prior to dosing. In Arms CA, CB, and CC AZD4635 will be administered as 75 mg or 50 mg capsules. Additionally, in Arm CA, AZD4635 will also be administered at 150 mg and 200 mg, or a lower dose of 125 mg or 100 mg may be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone acetate 1000 mg PO QD will be given with prednisone BID. The patient must receive abiraterone/prednisone according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary abiraterone/ prednisone dose modifications may follow institutional standard practice.~Abiraterone acetate is supplied in 250 mg tablets.
Study: NCT03307642

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text message notification
Description: Three text messages will be sent to 50% of the parents, scheduled around the standard methods of communication
Study: NCT02184325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kiddi® Pharmaton Fizz, effervescent tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator product
Description: active substances: Vitamin A, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, Manganese, Copper, Calcium, Magnesium, Phosphorous, Iron, Zinc, Sodium, Molybden
Study: NCT04330950

Intervention type: OTHER
Intervention: Neurocognitive tests
Description: Preoperative: Battery of neurocognitive tests and questionnaires (MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey) Postoperative in PACU: NuDESC test Postoperative 30 days: 10 minute phone interview
Study: NCT02576821

Intervention type: OTHER
Group type: OTHER
Intervention: Neurological examinations

Intervention type: OTHER
Group type: OTHER
Intervention: Neurological examinations

Intervention type: OTHER
Group type: OTHER
Intervention: Neurological examinations

Intervention type: OTHER
Group type: OTHER
Intervention: Neurological examinations

Intervention type: OTHER
Group type: OTHER
Intervention: Neurological examinations

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological examinations

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological examinations

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological examinations

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological examinations

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological examinations

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical examinations

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical examinations

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical examinations

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical examinations

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical examinations

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI 3T

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI 3T

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI 3T

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI 3T

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI 3T

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI 7T

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI 7T

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI 7T

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI 7T

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI 7T
Study: NCT01101152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate
Description: Tablets of 50 mg,100 mg; Dosing regimen: 50, 100, 200 mg/day; 1 week for each dose regimen;~1 tablet a day for doses of 50 and 100mg/day, and 2 tablets of 100mg for dose of 200mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate
Description: Tablets of 50 mg,100 mg; Dosing regimen: 50, 100, 200 mg/day; 1 week for each dose regimen;~1 tablet a day for doses of 50 and 100mg/day, and 2 tablets of 100mg for dose of 200mg/day
Study: NCT00411996

Intervention type: DRUG
Group type: OTHER
Intervention: indinavir/ritonavir
Description: IDV/r 600/100 mg BID + rifampicin OD for at least 2 weeks
Study: NCT02740985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide 160 mg PO QD will be dosed per the approved package insert. The patient must receive enzalutamide according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary enzalutamide dose modifications may follow institutional standard practice.~Enzalutamide is supplied as 40 mg soft gelatin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab 1500 mg will be given by IV infusion on Days 1 and 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients in Cohort CC will receive docetaxel 75 mg/m² by IV infusion according to institutional standards of practice on Day 1 of each treatment cycle. If a patient's body surface area is greater than 2.2 m², the docetaxel dose will be adjusted to a body surface area of 2.2 m².~The patient should be pre-medicated with oral dexamethasone 8 mg (or equivalent) twice daily starting the day prior to treatment for a total of 3 days, or according to institutional standards of practice.
Study: NCT02065284

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic Auditory Stimulation (RAS)
Description: Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic Auditory Stimulation (RAS)
Description: Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic Auditory Stimulation (RAS)
Description: Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.
Study: NCT02605447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 months of dual antiplatelet therapy (DAPT)
Description: 3 months of P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) plus 15-months of aspirin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNERGY Stent System
Description: SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Study: NCT00696865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2624
Description: oral suspension, 3 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03628430

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine with epinephrine
Description: Local anesthesia with lidocaine with epinephrine
Study: NCT01538199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared radiation via Transcranial LED Therapy
Description: The subject will lie down comfortably on a exam bed . The sites of application of TLT (left and right forehead) will be inspected for any skin lesions (e.g. laceration or signs of inflammation) which would contraindicate the treatment. The subject will wear protective eyewear in the form of goggles or eye pads.~The staff administering the TLT will be careful not to shine the light in or near the eyes of the subject. The two OLS devices will be secured in position with the use of a Hair Net. The delivery of the TLT is expected to last 20 min total (simultaneous application on the left and right forehead). The subject will be asked to rest for five minutes after the delivery of TLT. The skin at the sites of the application will be inspected again prior to dismissing the subject.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The sham device does not emit near-infrared radiation.
Study: NCT04772794

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fraction of inspired oxygen
Description: after induction of general anaesthesia, different fraction of inspired oxygen will be given to patient according to their group allocation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fraction of inspired oxygen
Description: after induction of general anaesthesia, different fraction of inspired oxygen will be given to patient according to their group allocation
Study: NCT03628430

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine with epinephrine
Description: Local anesthesia with lidocaine with epinephrine
Study: NCT04940169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior cruciate ligament recontruction
Description: Firstly graft is harvested with help of arthroscopy femoral and tibial tunnels created then graft placed into tunnels
Study: NCT03628430

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: sodium bicarbonate as adjuvant to lidocaine with epinephrine in Local anesthesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline as adjuvant to lidocaine with epinephrine in Local anesthesia
Study: NCT04617587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Intervention
Description: The early intervention (EI) is delivered during the NICU stay. It is a multisensory intervention which consists in three parts: parental training, massage therapy and visual interaction. The EI is first focused on parental training, according to PremieStart Protocol, in order to train parents to: recognize signs of infant stress and alert-available behavior through the identification of infant's behavioral states; adopt principles of graded stimulation; sustain infant's attention and respond to infant's cues; optimize interactions and avoid overwhelming infants through facilitation strategies. The program is held in eight main sessions and one additional post-discharge session. In addition, parents are trained and invited to daily promote preterm baby massage therapy and visual interaction (visual fixation/tracking and visual attention).
Study: NCT03664973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus plane block
Description: Local anesthetic infusion though a peripheral nerve catheter placed on the 5th rib under the serratus plane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus plane block
Description: Local anesthetic infusion though a peripheral nerve catheter placed on the 5th rib under the serratus plane
Study: NCT03224975

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: During fMRI, patients and control group will have to thought to seven painful memories, seven emotional memories not painful, seven neutral memories. At every memory there is control test. It is to count backwards.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: During fMRI, patients and control group will have to thought to seven painful memories, seven emotional memories not painful, seven neutral memories. At every memory there is control test. It is to count backwards.
Study: NCT05487560

Intervention type: DRUG
Intervention: Esomezol Cap
Description: Esomezol Cap, Once daily administered per the locally approved product information

Intervention type: DRUG
Intervention: Esomezol Cap
Description: Esomezol Cap, Once daily administered per the locally approved product information
Study: NCT02836301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control ending - Uplifting
Description: The control ending is emotionally uplifting. In this video, the decedent previously registered as an organ donor through online registration and discussed his decision with family. The scene cuts to the family affirming the deceased's wish. In the next scene, the donor family and recipient meet for the first time, ending with a plea from both parties for viewers to register for donation.
Study: NCT02210871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.
Study: NCT03579368

Intervention type: DEVICE
Group type: OTHER
Intervention: Symfony implantation
Description: Bilateral Symfony IOL Implantation